American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 426-437 , March 2009

Hospital Performance and Differences by Kidney Function in the Use of Recommended Therapies After Non–ST-Elevation Acute Coronary Syndromes

  • Uptal D. Patel, MD

      Affiliations

    • Division of Nephrology, Duke University Medical Center, Durham, NC
    • Duke Clinical Research Institute, Durham, NC
    • Corresponding Author InformationAddress correspondence to Uptal D. Patel, MD, Duke Clinical Research Institute, DUMC Box 3646, Nephrology, Durham, NC 27710
    • ,
  • Fang-Shu Ou, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC
    • ,
  • W. Brian Gibler, MD

      Affiliations

    • Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, OH
    • ,
  • Charles V. Pollack Jr, MD, MA

      Affiliations

    • Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia, PA
    • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC
    • ,
  • Matthew T. Roe, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC

Received 7 May 2008 ,Accepted 30 September 2008.

References 

  1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560–2572
  4. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4–S36
  5. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  6. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42:201–208
  7. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587–1592
  8. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: A high-risk combination. Ann Intern Med. 2002;137:563–570
  9. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: Findings from the Global Registry of Acute Coronary Events (GRACE). Heart. 2003;89:1003–1008
  10. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144:226–232
  11. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med. 2002;137:555–562
  12. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384
  13. Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med. 2006;119:248–254
  14. Roe MT, Peterson ED, Newby LK, et al. The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2006;151:1205–1213
  15. Alexander KP, Roe MT, Chen AY, et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005;46:1479–1487
  16. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA. 2006;295:1912–1920
  17. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269–1276
  18. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project. JAMA. 1998;279:1351–1357
  19. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the Guidelines for cardiovascular secondary prevention: Pilot results. Arch Intern Med. 2004;164:203–209
  20. Roe MT, Chen AY, Delong ER, et al. Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. Am Heart J. 2008;156:185–192
  21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  22. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—Summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  23. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: A generalized estimating equation approach. Biometrics. 1988;44:1049–1060
  24. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox. JAMA. 2004;291:1864–1870
  25. Bradley EH, Herrin J, Wang Y, et al. Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA. 2004;292:1563–1572
  26. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–1324
  27. Safford M, Eaton L, Hawley G, et al. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003;163:922–928
  28. Smith NL, Chen L, Au DH, McDonell M, Fihn SD. Cardiovascular risk factor control among veterans with diabetes: The ambulatory care quality improvement project. Diabetes Care. 2004;27(suppl 2):B33–B38
  29. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516–1520
  30. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635–2645
  31. Hayward RA, Asch SM, Hogan MM, Hofer TP, Kerr EA. Sins of omission. J Gen Intern Med. 2005;20:686–691
  32. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003;41:718–724
  33. Collet JP, Montalescot G, Agnelli G, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: Benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes (The Global Registry of Acute Coronary Events). Eur Heart J. 2005;26:2285–2293
  34. Brown DL. Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart. 2003;89:535–537
  35. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108–3116
  36. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839–2844
  37. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104
  38. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473–484
  39. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: How concerned should we be by the rise in serum creatinine?. J Am Geriatr Soc. 2002;50:1297–1300
  40. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? (Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function). Arch Intern Med. 2000;160:2645–2650
  41. Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) Study. Circulation. 2004;110:3667–3673
  42. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med. 2000;160:685–693
  43. Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol. 1992;2:1608–1616
  44. BHAT Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707–1714
  45. Lee TH. Eulogy for a quality measure. N Engl J Med. 2007;357:1175–1177
  46. Roe MT, Boden W, Chen AY, et al. Is the “hub-and-spoke” model working? (Patterns of transfer for high-risk acute coronary syndromes patients from community hospitals without revascularization capacity). J Am Coll Cardiol 43. 2004;43(suppl A):S1A;(; abstr)
  47. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006;1:796–801
  48. Winkelmayer WC, Levin R, Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol. 2008;3:1415–1422

 Originally published online as doi:10.1053/j.ajkd.2008.09.024 on December 22, 2008.

PII: S0272-6386(08)01609-0

doi: 10.1053/j.ajkd.2008.09.024

American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 426-437 , March 2009

Article Tools

* Image Usage & Resolution